Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 0.80 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.61 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.61 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.61 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.61 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6556900 | 1.00 | TACR1 (0.80) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| Hydrochloric Acid SCHEMBL6557032 | 1.00 | TACR1 (0.80) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| SCHEMBL6554885 | 0.99 | TACR1 (0.81) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| SCHEMBL6554893 | 0.99 | TACR1 (0.81) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| SCHEMBL6554903 | 0.99 | TACR1 (0.81) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| Hydrochloric Acid SCHEMBL6555120 | 0.93 | TACR1 (0.85) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| Hydrochloric Acid SCHEMBL6556027 | 0.93 | TACR1 (0.85) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| Hydrochloric Acid SCHEMBL6556033 | 0.93 | TACR1 (0.85) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| SCHEMBL6555218 | 0.92 | TACR1 (0.86) | TACR1HTR1AHTR2AHTR2CHRH1 | |
| SCHEMBL6555224 | 0.92 | TACR1 (0.86) | TACR1HTR1AHTR2AHTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| EP-1411946-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | Pfizer Products Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030139443-A1 | Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses | BRONK BRIAN SCOTT (US) | 2003-07-24 | — | — | US | claimed |
| US-6562335-B1 | NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy | PFIZER, INC. | 2003-05-13 | — | — | US | claimed |
| WO-2003009848-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | PFIZER PRODUCTS INC. (US) | 2003-02-06 | — | — | WO | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-0854720-B1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0659409-A2 | Substance 1 antagonists for the inhibition of angiogenesis | PFIZER INC. (US) | 1995-06-28 | — | — | EP | claimed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | claimed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | claimed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0436334-B1 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER (US) | 1994-12-07 | — | — | EP | claimed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | claimed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | claimed |
| EP-0610021-A1 | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-10 | — | — | EP | claimed |
| US-5232929-A | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use | PFIZER INC. (US) | 1993-08-03 | — | — | US | claimed |
| EP-0436334-A2 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER INC. (US) | 1991-07-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | TACR1 190/4885HTR1A 629/4885HTR2A 1356/4885 |
| US-20030139443-A1 | Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses | NPSR1, NTSR1, TACR1 | TACR1 3/4885HTR1A 44/4885HTR2A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.